- In early May 2026, Syndax Pharmaceuticals reported first-quarter 2026 revenue of US$64.86 million and a net loss of US$42.67 million, while also highlighting 12 Revuforj (revumenib) abstracts accepted for presentation at the June 2026 European Hematology Association Congress that showcase activity across multiple acute leukemia settings and genetic subtypes.
- An important angle for investors is the breadth of real-world and combination data for Revuforj, including post-transplant maintenance and frontline use, which further clarifies how this first-in-class menin inhibitor may be integrated across the acute leukemia treatment continuum.
- We will now examine how this expanded Revuforj dataset, particularly the real-world ROAR study findings, may influence Syndax's investment narrative.
Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
Syndax Pharmaceuticals Investment Narrative Recap
To own Syndax today, you need to believe Revuforj and Niktimvo can grow into durable, label-expanded franchises while the company narrows its heavy losses. The new EHA 2026 Revuforj abstracts, especially the ROAR real-world study, matter mainly as clinical validation that could support broader use over time. In the near term, the key catalyst remains further Revuforj data and adoption, while the biggest risk is the company’s reliance on just two commercial assets and ongoing net losses.
The most relevant recent announcement here is Syndax’s first quarter 2026 update, with revenue of US$64.86 million and a net loss of US$42.67 million. That print underlines how closely the financial story already tracks Revuforj uptake, so any shift in real-world outcomes or label breadth from the EHA dataset could eventually influence both top line growth and the company’s path toward profitability.
Yet behind the promise of Revuforj’s expanded data, investors should be aware that...
Read the full narrative on Syndax Pharmaceuticals (it's free!)
Syndax Pharmaceuticals' narrative projects $748.0 million revenue and $110.2 million earnings by 2029. This requires 63.1% yearly revenue growth and a $395.6 million earnings increase from -$285.4 million today.
Uncover how Syndax Pharmaceuticals' forecasts yield a $39.50 fair value, a 89% upside to its current price.
Exploring Other Perspectives
The most cautious analysts were assuming around US$550.7 million of revenue and US$81.2 million of earnings by 2029, and focus heavily on the risk that tougher real world evidence and pricing scrutiny could restrain Revuforj’s long term contribution, so you should see their view as a much more pessimistic counterweight that might shift again once the full EHA data are in.
Explore 6 other fair value estimates on Syndax Pharmaceuticals - why the stock might be worth over 4x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Syndax Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Syndax Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Syndax Pharmaceuticals' overall financial health at a glance.
Curious About Other Options?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.
- Find 47 companies with promising cash flow potential yet trading below their fair value.
- Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com